Literature DB >> 33478099

Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers.

Xiangyu Li1, Woonghee Kim1, Muhammad Arif1, Chunxia Gao2, Andreas Hober1, David Kotol1, Linnéa Strandberg1, Björn Forsström1, Åsa Sivertsson1, Per Oksvold1, Hasan Turkez3, Morten Grøtli2, Yusuke Sato4,5, Haruki Kume5, Seishi Ogawa4,6, Jan Boren7, Jens Nielsen8,9, Mathias Uhlen1, Cheng Zhang1,10, Adil Mardinoglu1,11.   

Abstract

Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and plays an important oncological role in cancer. However, the association of PKM expression and the survival outcome of patients with different cancers is controversial. We employed systems biology methods to reveal prognostic value and potential biological functions of PKM transcripts in different human cancers. Protein products of transcripts were shown and detected by western blot and mass spectrometry analysis. We focused on different transcripts of PKM and investigated the associations between their mRNA expression and the clinical survival of the patients in 25 different cancers. We find that the transcripts encoding PKM2 and three previously unstudied transcripts, namely ENST00000389093, ENST00000568883, and ENST00000561609, exhibited opposite prognostic indications in different cancers. Moreover, we validated the prognostic effect of these transcripts in an independent kidney cancer cohort. Finally, we revealed that ENST00000389093 and ENST00000568883 possess pyruvate kinase enzymatic activity and may have functional roles in metabolism, cell invasion, and hypoxia response in cancer cells. Our study provided a potential explanation to the controversial prognostic indication of PKM, and could invoke future studies focusing on revealing the biological and oncological roles of these alternative spliced variants of PKM.

Entities:  

Keywords:  PKM; alternative splicing; cancer; transcriptomics

Year:  2021        PMID: 33478099      PMCID: PMC7835739          DOI: 10.3390/cancers13020348

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  70 in total

1.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.

Authors:  Jill D Dombrauckas; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochemistry       Date:  2005-07-12       Impact factor: 3.162

Review 2.  PKM2, cancer metabolism, and the road ahead.

Authors:  Talya L Dayton; Tyler Jacks; Matthew G Vander Heiden
Journal:  EMBO Rep       Date:  2016-11-17       Impact factor: 8.807

3.  Integrated molecular analysis of clear-cell renal cell carcinoma.

Authors:  Yusuke Sato; Tetsuichi Yoshizato; Yuichi Shiraishi; Shigekatsu Maekawa; Yusuke Okuno; Takumi Kamura; Teppei Shimamura; Aiko Sato-Otsubo; Genta Nagae; Hiromichi Suzuki; Yasunobu Nagata; Kenichi Yoshida; Ayana Kon; Yutaka Suzuki; Kenichi Chiba; Hiroko Tanaka; Atsushi Niida; Akihiro Fujimoto; Tatsuhiko Tsunoda; Teppei Morikawa; Daichi Maeda; Haruki Kume; Sumio Sugano; Masashi Fukayama; Hiroyuki Aburatani; Masashi Sanada; Satoru Miyano; Yukio Homma; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-06-24       Impact factor: 38.330

4.  Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers.

Authors:  Yangjun Zhang; Libin Yan; Jin Zeng; Hui Zhou; Haoran Liu; Gan Yu; Weimin Yao; Ke Chen; Zhangqun Ye; Hua Xu
Journal:  Oncogene       Date:  2019-08-07       Impact factor: 9.867

5.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism.

Authors:  Cynthia V Clower; Deblina Chatterjee; Zhenxun Wang; Lewis C Cantley; Matthew G Vander Heiden; Adrian R Krainer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

6.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

7.  M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.

Authors:  Marta Cortés-Cros; Christelle Hemmerlin; Stephane Ferretti; Juan Zhang; John S Gounarides; Hong Yin; Alban Muller; Anne Haberkorn; Patrick Chene; William R Sellers; Francesco Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

8.  Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.

Authors:  Wen-Wen Lv; Dahai Liu; Xing-Cun Liu; Tie-Nan Feng; Lei Li; Bi-Yun Qian; Wen-Xing Li
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

9.  Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.

Authors:  Libin Wei; Yuanyuan Dai; Yuxin Zhou; Zihao He; Jingyue Yao; Li Zhao; Qinglong Guo; Lin Yang
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

Review 10.  Transcription Factors in Cancer: When Alternative Splicing Determines Opposite Cell Fates.

Authors:  Silvia Belluti; Giovanna Rigillo; Carol Imbriano
Journal:  Cells       Date:  2020-03-20       Impact factor: 6.600

View more
  3 in total

1.  N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.

Authors:  Aierpati Maimaiti; Abudireheman Tuersunniyazi; Xianghong Meng; Yinan Pei; Wenyu Ji; Zhaohai Feng; Lei Jiang; Zengliang Wang; Maimaitijiang Kasimu; Yongxin Wang; Xin Shi
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

2.  Single-Cell FISH Analysis Reveals Distinct Shifts in PKM Isoform Populations during Drug Resistance Acquisition.

Authors:  Seong Ho Kim; Ji Hun Wi; HyeRan Gwak; Eun Gyeong Yang; So Yeon Kim
Journal:  Biomolecules       Date:  2022-08-06

3.  Expression of HK2, PKM2, and PFKM Is Associated with Metastasis and Late Disease Onset in Breast Cancer Patients.

Authors:  Mehreen Ishfaq; Nabiha Bashir; Syeda Kiran Riaz; Shumaila Manzoor; Jahangir Sarwar Khan; Yamin Bibi; Rokayya Sami; Amani H Aljahani; Saif A Alharthy; Ramla Shahid
Journal:  Genes (Basel)       Date:  2022-03-20       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.